Patents Assigned to Aduro Biotech
-
Patent number: 11959924Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: GrantFiled: June 28, 2021Date of Patent: April 16, 2024Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20220135671Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: ApplicationFiled: November 30, 2020Publication date: May 5, 2022Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans VAN EENENNAAM, Andrea VAN ELSAS, Erik VOETS, Paul VINK, David Lutje HULSIK
-
Publication number: 20210379183Abstract: Formulation and use of antibodies which bind human APRIL for the treatment of conditions related to IgA overproduction or deposition, including IgA Nephropathy.Type: ApplicationFiled: May 28, 2021Publication date: December 9, 2021Applicants: CHINOOK THERAPEUTICS, INC., ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Teun VAN DE LAAR, Somayeh HONARMAND, John DULOS, Eduard DE COCK
-
Publication number: 20210325404Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: ApplicationFiled: June 28, 2021Publication date: October 21, 2021Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Publication number: 20210246122Abstract: The present invention relates to triazine compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: ApplicationFiled: June 14, 2019Publication date: August 12, 2021Applicant: Aduro Biotech, Inc.Inventors: George Edwin Katibah, Jung Yun Kim, Chudi Obioma Ndubaku, Meiliana Tjandra, Tucker Curran Roberts
-
Publication number: 20210221900Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: ApplicationFiled: March 29, 2021Publication date: July 22, 2021Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 11047864Abstract: The invention relates to a method for obtaining APRIL-binding peptides. With this method APRIL-binding peptides may be obtained and/or selected. Further aspects of the invention relate to a cell comprising a nucleotide sequence coding for an APRIL-binding peptide according to the invention, a process for producing an APRIL-binding peptide and the APRIL-binding peptide obtainable in the production process and/or the selection method. In view of the possible utility of the APRIL-binding peptides according to the invention, further aspects of the invention relate to diagnostic uses of an APRIL binding peptide of the invention.Type: GrantFiled: September 11, 2018Date of Patent: June 29, 2021Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Lilian Driessen, Jan Paul Medema
-
Patent number: 10961316Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: GrantFiled: August 12, 2019Date of Patent: March 30, 2021Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 10851164Abstract: The present invention relates to anti-SIRP? antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.Type: GrantFiled: April 13, 2018Date of Patent: December 1, 2020Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Erik Voets, Paul Vink, David Lutje Hulsik
-
Patent number: 10808030Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.Type: GrantFiled: October 2, 2017Date of Patent: October 20, 2020Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
-
Publication number: 20200282049Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and prefereably Rp,Rp stereosiomers thereof.Type: ApplicationFiled: May 18, 2020Publication date: September 10, 2020Applicants: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas W. Dubensky, JR., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
-
Patent number: 10738056Abstract: The present invention relates to pyrazolopyrimidinone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating autoimmune, inflammatory, and neurodegenerative diseases by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.Type: GrantFiled: September 14, 2018Date of Patent: August 11, 2020Assignee: Aduro BioTech Inc.Inventors: Chudi Obioma Ndubaku, George Edwin Katibah, Tucker Curran Roberts, Leonard Sung, Stephane Ciblat, Franck Raeppel, Vu Linh Ly, Yeeman K. Ramtohul, Taras Rybak, Mariam Zaky, Laura Gillard, Hossein Ismaili
-
Publication number: 20200179431Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5? CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: ApplicationFiled: October 21, 2019Publication date: June 11, 2020Applicant: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, JR.
-
Patent number: 10653774Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are substantially pure 2?,5?,2?,5? and 2?,5?,3?,5? CDNs, and preferably Rp,Rp stereoisomers thereof.Type: GrantFiled: July 31, 2017Date of Patent: May 19, 2020Assignees: ADURO BIOTECH, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura H. Glickman, Russell E. Vance
-
Publication number: 20200079859Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: ApplicationFiled: August 12, 2019Publication date: March 12, 2020Applicant: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema
-
Patent number: 10526609Abstract: The present invention provides nucleic acid and protein sequences that enhance the expression of fusion proteins by host cells, and in particular bacterial species, together with methods use thereof. While described hereinafter in terms of expression of fusion proteins by Listeria monocytogenes, the present invention is applicable to expression of fusion proteins generally.Type: GrantFiled: July 31, 2017Date of Patent: January 7, 2020Assignee: ADURO BIOTECH, INC.Inventors: Peter M. Lauer, William G. Hanson
-
Patent number: 10494436Abstract: The present invention relates to anti-PD-1 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. These antibodies have CDRs as provided in the enclosed sequences. Also part of the invention are nucleic acids encoding these antibodies, expression vectors comprising such nucleotide sequences and host cells that comprise said nucleotide sequences or expression vectors.Type: GrantFiled: July 28, 2017Date of Patent: December 3, 2019Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Carlos Ricardo Rodrigues Dos Reis
-
Patent number: 10449211Abstract: The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2?-fluoro substituted, bis-3?,5?CDNs, and most preferably one or more 2?,2?-diF-Rp,Rp, bis-3?,5?CDNs.Type: GrantFiled: March 9, 2016Date of Patent: October 22, 2019Assignee: ADURO BIOTECH, INC.Inventors: George Edwin Katibah, David Kanne, Leonard Sung, Kelsey Gauthier, Laura Hix Glickman, Justin Leong, Sarah M. McWhirter, Thomas W. Dubensky, Jr.
-
Patent number: 10414789Abstract: It is an object of the present invention to provide novel and highly active cyclic-di-nucleotide (CDN) immune stimulators that activates DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides that induce STING-dependent TBK1 activation, wherein the cyclic purine dinuclotides present in the composition are substantially pure Rp,Rp or Rp,Sp stereoisomers, and particularly substantially pure Rp,Rp, or RpSp CDN thiophosphate diastereomers.Type: GrantFiled: June 22, 2017Date of Patent: September 17, 2019Assignee: ADURO BIOTECH, INC.Inventors: Thomas W. Dubensky, Jr., David B. Kanne, Meredith Lai Ling Leong, Edward Emile Lemmens, Laura Hix Glickman
-
Patent number: 10377830Abstract: The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the VH and VL domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.Type: GrantFiled: May 14, 2018Date of Patent: August 13, 2019Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.Inventors: Hans van Eenennaam, Andrea van Elsas, David Lutje Hulsik, Jan Paul Medema